We Can Quit2 (WCQ2): a community-based intervention on smoking cessation for women living in disadvantaged areas of Ireland-study protocol for a pilot cluster randomised controlled trial.
Cluster randomised controlled trial
Community-based intervention
Feasibility study
PRECIS-2
Pilot trial
Process evaluation
Smoking cessation
Social and health inequalities
Women and smoking
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
10
2018
accepted:
01
10
2019
entrez:
3
12
2019
pubmed:
4
12
2019
medline:
4
12
2019
Statut:
epublish
Résumé
Tobacco use is the leading cause of preventable death in Ireland with almost 6000 smokers dying each year from smoking-related diseases. The 'We Can Quit2' (WCQ2) study is a pilot pragmatic two-arm, parallel-group, cluster randomised trial that aims to explore the feasibility and acceptability of trial processes including recruitment and to estimate parameters to inform sample size estimates needed for an effectiveness trial. This future trial will assess the effectiveness of a community-based smoking cessation intervention for women living in disadvantaged areas on short- and medium-term cessation rates. Four matched pairs of districts (eight clusters) selected by area level of deprivation, geographical proximity, and eligibility for free medical services will be randomised to receive either WCQ (behavioural support + access to Nicotine Replacement Therapy (NRT)) delivered over 12 weeks by trained Community Facilitators (CFs) or to a form of usual care, a one-to-one smoking cessation service delivered by Smoking Cessation Officers from Ireland's national health service, the Health Service Executive (HSE). Within each cluster, 24-25 women will be recruited (97 per arm; 194 in total) in 4 phases with consent obtained prior to cluster randomisation. The outcome measures will assess feasibility and acceptability of trial processes, including randomisation. Outcome data for a future definitive intervention (biochemically validated smoking abstinence) will be collected at end of programme (12 weeks) and at 6 months. WCQ2 has an embedded process evaluation using both qualitative and quantitative methods. This will be conducted (semi-structured client and CF interviews, intervention delivery checklist, and diary) to explore acceptability of trial processes, intervention fidelity, trial context, and implementation. Trial processes will be assessed against domains of the PRECIS-2 wheel to inform a future definitive trial design. Data from this pilot trial will inform the design and sample size for a full cluster randomised trial to determine the effectiveness of an intervention tailored to disadvantaged women in improving smoking cessation rates. It will provide transferable learning on the systems and implementation strategies needed to support effective design of future pragmatic community-based trials which address health promotion interventions for women in disadvantaged communities. Concurrent to publication. Controlled trials ISRCTN74721694.
Sections du résumé
BACKGROUND
BACKGROUND
Tobacco use is the leading cause of preventable death in Ireland with almost 6000 smokers dying each year from smoking-related diseases. The 'We Can Quit2' (WCQ2) study is a pilot pragmatic two-arm, parallel-group, cluster randomised trial that aims to explore the feasibility and acceptability of trial processes including recruitment and to estimate parameters to inform sample size estimates needed for an effectiveness trial. This future trial will assess the effectiveness of a community-based smoking cessation intervention for women living in disadvantaged areas on short- and medium-term cessation rates.
METHODS/DESIGN
METHODS
Four matched pairs of districts (eight clusters) selected by area level of deprivation, geographical proximity, and eligibility for free medical services will be randomised to receive either WCQ (behavioural support + access to Nicotine Replacement Therapy (NRT)) delivered over 12 weeks by trained Community Facilitators (CFs) or to a form of usual care, a one-to-one smoking cessation service delivered by Smoking Cessation Officers from Ireland's national health service, the Health Service Executive (HSE). Within each cluster, 24-25 women will be recruited (97 per arm; 194 in total) in 4 phases with consent obtained prior to cluster randomisation. The outcome measures will assess feasibility and acceptability of trial processes, including randomisation. Outcome data for a future definitive intervention (biochemically validated smoking abstinence) will be collected at end of programme (12 weeks) and at 6 months. WCQ2 has an embedded process evaluation using both qualitative and quantitative methods. This will be conducted (semi-structured client and CF interviews, intervention delivery checklist, and diary) to explore acceptability of trial processes, intervention fidelity, trial context, and implementation. Trial processes will be assessed against domains of the PRECIS-2 wheel to inform a future definitive trial design.
DISCUSSION
CONCLUSIONS
Data from this pilot trial will inform the design and sample size for a full cluster randomised trial to determine the effectiveness of an intervention tailored to disadvantaged women in improving smoking cessation rates. It will provide transferable learning on the systems and implementation strategies needed to support effective design of future pragmatic community-based trials which address health promotion interventions for women in disadvantaged communities.
TRIAL REGISTRATION
BACKGROUND
Concurrent to publication. Controlled trials ISRCTN74721694.
Identifiants
pubmed: 31788324
doi: 10.1186/s40814-019-0511-9
pii: 511
pmc: PMC6875165
doi:
Types de publication
Journal Article
Langues
eng
Pagination
138Informations de copyright
© The Author(s). 2019.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
BMJ. 2003 Jul 19;327(7407):154-7
pubmed: 12869461
Addiction. 2005 Mar;100(3):299-303
pubmed: 15733243
Addiction. 2013 Oct;108(10):1711-21
pubmed: 23834141
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
Pilot Feasibility Stud. 2016 Oct 21;2:64
pubmed: 27965879
Qual Quant. 2018;52(4):1893-1907
pubmed: 29937585
Am J Community Psychol. 2012 Sep;50(1-2):129-40
pubmed: 22124619
PLoS One. 2016 Mar 15;11(3):e0150205
pubmed: 26978655
Trials. 2013 Oct 25;14:353
pubmed: 24160371
Trials. 2014 Jul 03;15:264
pubmed: 24993581
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
J Clin Epidemiol. 2015 Nov;68(11):1375-9
pubmed: 26146089
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Health Educ Q. 1988 Winter;15(4):351-77
pubmed: 3068205
Qual Health Res. 2018 Feb;28(3):381-388
pubmed: 29298584
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Implement Sci. 2007 Nov 30;2:40
pubmed: 18053122
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
J Epidemiol Community Health. 2006 Sep;60 Suppl 2:7-12
pubmed: 17708005
Res Nurs Health. 2007 Feb;30(1):45-60
pubmed: 17243107
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663
BMJ. 2015 May 08;350:h2147
pubmed: 25956159